Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	240.04M
Revenue (ttm)	351.41M
Net Income (ttm)	1.81M
Shares Out	160.03M
EPS (ttm)	0.01
PE Ratio	150.00
Forward PE	8.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,035,930
Open	1.480
Previous Close	1.490
Day's Range	1.435 - 1.530
52-Week Range	1.340 - 9.010
Beta	0.37
Analysts	Buy
Price Target	9.75 (+547.84%)
Earnings Date	May 8, 2025

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the tre...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD
• Website: https://www.ironwoodpharma.com

Analyst Forecast

According to 4 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $9.75, which is an increase of 547.84% from the latest price.

Price Target

$9.75

(547.84% upside)

Analyst Consensus: Buy